 |
Top 10 Eye Disease and Blindness treatment startups in USA
Updated: May 09, 2024 |
1
Funding: $763.8M
Spark is a leader in the field of gene therapy, seeking to transform the lives of patients by developing potential one-time, life-altering treatments for debilitating genetic diseases. We initially are applying our integrated platform to treat rare diseases where no, or only palliative, therapies exist.
Spark is a leader in the field of gene therapy, seeking to transform the lives of patients by developing potential one-time, life-altering treatments for debilitating genetic diseases. We initially are applying our integrated platform to treat rare diseases where no, or only palliative, therapies exist.
2
Funding: $694.9M
Pliant Therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases.
Pliant Therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases.
3
Funding: $317.8M
Emendo Biotherapeutics develops gene editing platform to expand the list of diseases amenable to treatment with gene editing, resulting in a pipeline of hematology and ophthalmology programs.
Emendo Biotherapeutics develops gene editing platform to expand the list of diseases amenable to treatment with gene editing, resulting in a pipeline of hematology and ophthalmology programs.
4
Funding: $218.5M
Avedro is a privately held medical device and pharmaceutical company advancing the science and technology of corneal cross-linking.
Avedro is a privately held medical device and pharmaceutical company advancing the science and technology of corneal cross-linking.
5
Funding: $173.4M
IDx is a leading AI diagnostics company on a mission to transform the quality, accessibility, and affordability of healthcare. The company’s first product, IDx-DR, is an FDA-cleared AI-based diagnostic system designed for use at the front lines of care to detect diabetic retinopathy. IDx is developing additional AI-based diagnostic algorithms for the detection of macular degeneration, glaucoma, Alzheimer’s disease, cardiovascular disease, and stroke risk.
IDx is a leading AI diagnostics company on a mission to transform the quality, accessibility, and affordability of healthcare. The company’s first product, IDx-DR, is an FDA-cleared AI-based diagnostic system designed for use at the front lines of care to detect diabetic retinopathy. IDx is developing additional AI-based diagnostic algorithms for the detection of macular degeneration, glaucoma, Alzheimer’s disease, cardiovascular disease, and stroke risk.
6
Funding: $153.9M
Through dedication and innovation, Second Sight's mission is to develop, manufacture and market implantable visual prosthetics to enable blind individuals to achieve greater independence. The Argus II Retinal Prosthesis System (“Argus II”) is also known as the bionic eye or the retinal implant. It is intended to provide electrical stimulation of the retina to induce visual perception in blind individuals with severe to profound Retinitis Pigmentosa.
Through dedication and innovation, Second Sight's mission is to develop, manufacture and market implantable visual prosthetics to enable blind individuals to achieve greater independence. The Argus II Retinal Prosthesis System (“Argus II”) is also known as the bionic eye or the retinal implant. It is intended to provide electrical stimulation of the retina to induce visual perception in blind individuals with severe to profound Retinitis Pigmentosa.
7
Funding: $139.5M
Gemini Therapeutics is a precision medicine company focused on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases.Their therapeutic candidates are matched to molecular abnormalities found in patients with high clinical need and our broad multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies.
Gemini Therapeutics is a precision medicine company focused on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases.Their therapeutic candidates are matched to molecular abnormalities found in patients with high clinical need and our broad multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies.
8
Funding: $120M
Aurion Biotechnologies is on mission is to cure leading forms of blindness and transform the lives of millions of patients, by developing a platform of advanced therapies to treat ocular diseases.
Aurion Biotechnologies is on mission is to cure leading forms of blindness and transform the lives of millions of patients, by developing a platform of advanced therapies to treat ocular diseases.
9
Funding: $118M
Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients (including with Thyroid Eye Disease ).
Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients (including with Thyroid Eye Disease ).
10
Funding: $112.7M
Meira Gene Therapy is argeting inherited retinal diseases with therapies designed to halt vision loss.
Meira Gene Therapy is argeting inherited retinal diseases with therapies designed to halt vision loss.
Ad
Advertise your startup
12
Funding: $57M
EyeQue is a maker of at home visual acuity tests. Dedicated to inspiring people to learn about & care for their eyes by putting affordable, accurate vision tests directly into their hands.
EyeQue is a maker of at home visual acuity tests. Dedicated to inspiring people to learn about & care for their eyes by putting affordable, accurate vision tests directly into their hands.
13
Funding: $56M
Visus Therapeutics is a clinical-stage company developing treatment for age-related long-sightedness.
Visus Therapeutics is a clinical-stage company developing treatment for age-related long-sightedness.
14
Funding: $46.8M
Surface Pharmaceuticals intends to advance state of the art treatments for ocular surface diseases.
Surface Pharmaceuticals intends to advance state of the art treatments for ocular surface diseases.
15
Funding: $47.4M
Eyenuk, Inc. is a global digital health company and leader in real-world AI eye screening for autonomous disease detection
Eyenuk, Inc. is a global digital health company and leader in real-world AI eye screening for autonomous disease detection
16
Funding: $43.1M
Opternative builds online eye exam, the most convenient way to get a prescription from an ophthalmologist for contacts and glasses. The exam can be taken from anywhere, at any time, and a doctor issued prescription can be used to shop everywhere. Eye exams for glasses and contact prescriptions are just the beginning. We envision a world where technology allows patients and doctors to connect to make all aspects of vision care more convenient, accessible and even fun!
Opternative builds online eye exam, the most convenient way to get a prescription from an ophthalmologist for contacts and glasses. The exam can be taken from anywhere, at any time, and a doctor issued prescription can be used to shop everywhere. Eye exams for glasses and contact prescriptions are just the beginning. We envision a world where technology allows patients and doctors to connect to make all aspects of vision care more convenient, accessible and even fun!
17
Funding: $42.4M
Abpro Therapeutics develops antibody drugs for cancer and vascular eye disease
Abpro Therapeutics develops antibody drugs for cancer and vascular eye disease
18
Funding: $26M
Simple Contacts allows you to take a vision test and reorder your contacts In just five minutes, without the office visit.
Simple Contacts allows you to take a vision test and reorder your contacts In just five minutes, without the office visit.
19
Funding: $17M
RetroSense Therapeutics is a biotechnology company that is developing a game-changing gene therapy to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). There are currently no FDA approved therapies to improve or restore vision in patients with these retinal degenerative conditions.
RetroSense Therapeutics is a biotechnology company that is developing a game-changing gene therapy to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). There are currently no FDA approved therapies to improve or restore vision in patients with these retinal degenerative conditions.
20
Funding: $10M
AEYE Health is a digital health company focused on automated, AI-based diagnostic screening solutions for retinal imaging. The company’s system is designed to enable clinicians to detect a variety of medical conditions, prevent blindness, and save lives.
AEYE Health is a digital health company focused on automated, AI-based diagnostic screening solutions for retinal imaging. The company’s system is designed to enable clinicians to detect a variety of medical conditions, prevent blindness, and save lives.
22
Funding: $8.1 m
We developed the world’s first smartphone based wavefront autorefractor, SVOne, to combat this global challenge. To date, the SVOne is used in over 300 eye clinics across the United States and in 23 countries. Today, the team continues to create industry-changing technology to reinvent the future of vision care.
We developed the world’s first smartphone based wavefront autorefractor, SVOne, to combat this global challenge. To date, the SVOne is used in over 300 eye clinics across the United States and in 23 countries. Today, the team continues to create industry-changing technology to reinvent the future of vision care.
24
Funding: $1.3M
Hemera Biosciences develops anti-complement gene-based therapies for the treatment of dry and wet age-related macular degeneration.
Hemera Biosciences develops anti-complement gene-based therapies for the treatment of dry and wet age-related macular degeneration.
25
Funding: $550K
Vital Art and Science, LLC (VAS) is the first company to create a patented, clinically validated, and FDA cleared Ophthalmic medical device that is available on the Apple App Store for all patients diagnosed with or concerned about maculopathy.
Vital Art and Science, LLC (VAS) is the first company to create a patented, clinically validated, and FDA cleared Ophthalmic medical device that is available on the Apple App Store for all patients diagnosed with or concerned about maculopathy.
26
Science develops advanced technologies with the goal to, over time, blur the line between medical devices and consumer electronics. It's focused on debilitating conditions for which there is a serious unmet medical need.
27
Claris works to improve lives by uniting unmet needs in ophthalmology with robust science and data-driven decision making